Alliances Announces 2021 State of the Science Summit
With a commitment to invest $30 million toward innovative and life-saving research by 2024, the Colorectal Cancer Alliance is taking a nuanced look at colorectal cancer research today to understand where it can have the greatest impact tomorrow.
The 2021 State of the Science Summit, set to meet virtually on October 4, is a last step in the Alliance’s research-field analysis before charting a five-year plan that will come to define its scientific strategy.
The summit will bring together multidisciplinary experts to collaboratively align on priority areas of research innovation and opportunity for colorectal advancements.
“We are looking for research domains where the Alliance can have the largest return on investment, answer questions that matter to patients, and ultimately save the most lives,” said Andrea Goodman, MSW, MPH, the Alliance’s Vice President of Patient Support and Research Strategy. “To do so, we are listening to patients, providers, and experts from every corner of the research community to understand where the greatest needs exist.”
Based on a forthcoming research landscape analysis commissioned by the Alliance, the summit will solicit detailed feedback in these areas, among others:
- Advancing new diagnostics and biomarkers
- Identifying new targets and improving therapies
- Overcoming health disparities and expanding screening
The need for research resulting in improved outcomes for colorectal cancer patients is clear. Despite significant advances in both the treatment and prevention of colorectal cancer, in the U.S. alone, more than 1.3 million people are living with a history of colorectal cancer in 2021. This includes approximately 150,000 new cases and 53,000 deaths this year.
A public report from the summit, which is invite-only, will be available in early November.
Top resources
FDA approves ColoSense, mt-sRNA screening test from Geneoscopy
ColoSense is a screening test for adults, 45 years of age or older, who are at average risk for developing colorectal cancer (CRC).
Christy Williams: Biomarker testing leads to successful treatment
Statistics suggested that Christy’s odds of survival were grim, so she leaned into her faith and kept a positive outlook. She tried to control what she could. And, critically, she received biomarker testing.
Dr. John Marshall joins the Alliance as Chief Medical Consultant
A veteran in the field of gastrointestinal cancer research, Dr. Marshall will share his leadership experience and scientific expertise to guide the Alliance’s patient support and research initiatives, particularly Project Cure CRC.